The Indian Lipid Lowering Drug Market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.
The Indian market is the world’s most potential market for lipid-lowering drugs and one of the fastest-growing markets in the world. The market size of India lipid-lowering drugs will continue to expand, and the growth rate will gradually increase. The cholesterol lowering drug market growth are emergence of new drug classes, changes in lifestyles, lack of exercise, and increase in intake of saturated & trans-fat. In addition, increase in smoking and alcohol consumption escalate the risk of high cholesterol, thus driving the market growth in India.
Growing prevalence of different cardiovascular diseases, which are caused by various factors such as increased obesity, changing food habits, higher alcohol consumption, and smoking is driving the cholesterol lowering drugs market. Growing awareness about bad cholesterol is one of the key drivers that is triggering the growth of the cholesterol lowering drugs market. Furthermore, increasing consumer preference for over-the-counter (OTC) drugs is another factor contributing to the market growth. In comparison to brand name drugs, OTC variants are usually more affordable. Additionally, the growing adoption of combination therapies that use statin with other cholesterol diminishing compounds, such as ezetimibe, is acting as another growth-inducing factor. Research has found statin-ezetimibe combination therapy to be capable of achieving near-normal lipid profiles in familial hypercholesterolemia patients reducing the risk of CVDs occurrence. Other factors, including improving healthcare infrastructure and growing health consciousness among consumers, are projected to drive the market.